Standard BioTools Inc. Long-Lived Assets
Standard BioTools Inc. (LAB) had Long-Lived Assets of $46.01 million as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Segment Reporting
us-gaap:NoncurrentAssets · last filed 2026-03-16
- 2025-12-31: Long-Lived Assets $46.01M.
- 2024-12-31: Long-Lived Assets $49.34M; Long-Lived Assets as first filed $71.38M.
- 2023-12-31: Long-Lived Assets $54.85M.
- 2022-12-31: Long-Lived Assets $59.53M.
| Period end | Long-Lived Assets | Long-Lived Assets as first filed |
|---|---|---|
| 2025-12-31 | $46.01M 10-K · filed 2026-03-16 | |
| 2024-12-31 | $49.34M 10-K · filed 2026-03-16 | $71.38M 10-K · filed 2025-03-11 |
| 2023-12-31 | $54.85M 10-K · filed 2026-03-16 | |
| 2022-12-31 | $59.53M 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |